Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2022
64
Period ended Dec 31, 2022
Change on a year earlier
-23.8%
84 in FY2021
History
8 years
Since FY2015
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 64 | -23.8% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 84 | -70.8% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 288 | -47.7% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 551 | -68.9% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 1,774 | +3.3% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,718 | +8.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,582 | +11.8% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1,415 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up sensipar / mimpara (cinacalcet — secondary hyperparathyroidism, legacy standalone disclosure) — worldwide product sales ($m)
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — U.S. product sales ($M)10 · FY2022
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)54 · FY2022
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)-24.0% · FY2022
Cite this data
StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M), annual FY2015–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_sensipar_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.